WW — WW International, Inc.

WW (WeightWatchers) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $168 million, down 10% year-over-year.
• Adjusted EBITDA: Loss of $1.8 million.
• End-of-Period Subscribers:
  • Behavioral: 2.5 million (down 25% year-over-year).
  • Core+: 537,000 (up 6% year-over-year).
  • Clinical: 197,000 (up 51% sequentially).
• Average Revenue Per User (ARPU): Increased 13% year-over-year to $20.59; Clinical ARPU over 4x higher than Behavioral ARPU.
• Adjusted Gross Margin: 73.6%, near record highs.
• Cash Position: Ended Q1 with $121 million in cash and equivalents.

2. Strategic Updates and Business Highlights:

• Transformation Strategy: Focus on integrating GLP-1 medications with behavioral support to enhance member outcomes and drive growth.
• Clinical Growth: Significant growth in Clinical subscription revenue (32% year-over-year), driven by the Med+ tier, which integrates clinical capabilities with behavioral support.
• Core+ Growth: Core+ subscriber growth attributed to enhanced virtual experiences, workshops led by registered dietitians and physicians, and medically tailored programs (e.g., menopause).
• Marketing Strategy: Increased brand awareness for GLP-1 offerings, resulting in a 10-point increase in general awareness and attracting new members.

3. Forward Guidance and Outlook:

• 2026 Financial Guidance: Reaffirmed revenue guidance of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million.
• Clinical Revenue Growth: Expected to represent 25% to 30% of total revenue in 2026, up from 16% in 2025.
• Subscriber Growth Expectations: Anticipated sequential growth in Clinical subscribers, though lower than Q1 due to seasonal normalization and adjusted marketing spend.

4. Challenges and Points of Concern:

• Behavioral Business Decline: Significant decline in Behavioral subscribers (down 25% year-over-year), indicating challenges in this segment.
• Market Pressures: Core business continues to face secular headwinds, necessitating a recalibration of marketing strategies.
• Debt Management: While cash position is stable, ongoing management of debt and interest expenses remains a focus, with a term loan interest rate of 10.5%.

5. Notable Q&A Insights:

• Subscriber Growth Dynamics: Q&A highlighted expectations for subscriber growth in both Behavioral and Clinical segments, with a focus on the balance between Core+ and Core offerings.
• Impact of GLP-1 Medications: The introduction of oral GLP-1 medications is seen as a positive development, expected to increase access and conversion rates.
• Brand Strategy Effectiveness: Marketing efforts have successfully increased awareness of WeightWatchers' GLP-1 offerings and attracted new members, with a notable percentage of Clinical subscribers being new to the platform.
• Menopause Program: The menopause initiative is contributing positively to Core+ growth, marking a significant development in the company's offerings.

Overall, while WeightWatchers is experiencing growth in its Clinical and Core+ segments, challenges persist in the Behavioral segment, necessitating strategic adjustments and a focus on long-term transformation.